<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NUTROPIN- somatropin 
			 </strong><br>Genentech, Inc.<br></p></div>
<h1>Nutropin<span class="Sup">®</span><br>[somatropin (rDNA origin) for injection]</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Nutropin<span class="Sup">®</span> [somatropin (rDNA origin) for
							injection] is a human growth hormone (hGH) produced by recombinant DNA
							technology. Nutropin has 191 amino acid residues and a
							molecular weight of 22,125 daltons. The amino acid sequence of
							the product is identical to that of pituitary‑derived human
							growth hormone. The protein is synthesized by a specific laboratory
							<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">E. coli</span> as a precursor
							consisting of the rhGH molecule preceded by the secretion signal from an
							<span class="Italics">E. coli</span> protein. This
							precursor is directed to the plasma membrane of the cell. The signal
							sequence is removed and the native protein is secreted into the
							periplasm so that the protein is folded appropriately as it is
							synthesized.</p>
<p>Nutropin is a highly purified preparation. Biological potency is
							determined using a cell proliferation bioassay.</p>
<p>Nutropin is a sterile, white, lyophilized powder intended for
							subcutaneous administration after reconstitution with Bacteriostatic
							Water for Injection, USP (benzyl alcohol preserved). The reconstituted
							product is nearly isotonic at a concentration of 5 mg/mL growth
							hormone (GH) and has a pH of approximately 7.4.</p>
<p>Each 5 mg Nutropin vial contains 5 mg
							(approximately 15 IU) somatropin, lyophilized with
							45 mg mannitol, 1.7 mg sodium phosphates
							(0.4 mg sodium phosphate monobasic and 1.3 mg sodium
							phosphate dibasic), and 1.7 mg glycine.</p>
<p>Each 10 mg Nutropin vial contains 10 mg
							(approximately 30 IU) somatropin, lyophilized with
							90 mg mannitol, 3.4 mg sodium phosphates
							(0.8 mg sodium phosphate monobasic and 2.6 mg sodium
							phosphate dibasic), and 3.4 mg glycine.</p>
<p>Bacteriostatic Water for Injection, USP is sterile water
							containing 0.9 percent benzyl alcohol per mL as an antimicrobial
							preservative packaged in a multidose vial. The diluent pH is
							4.5–7.0.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>General</h2>
<p class="First">In vitro and in vivo preclinical and
									clinical testing have demonstrated that Nutropin is
									therapeutically equivalent to pituitary‑derived human
									GH (hGH). Pediatric patients who lack adequate endogenous GH
									secretion, patients with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal insufficiency</span>, and
									patients with Turner syndrome that were treated with Nutropin
									resulted in an increase in growth rate and an increase in
									insulin‑like growth factor‑I
									(IGF‑I) levels similar to that seen with
									pituitary‑derived hGH.</p>
<p>Actions that have been demonstrated for Nutropin,
									somatrem, and/or pituitary‑derived hGH
									include:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<h3><span class="Bold">A. Tissue Growth</span></h3>
<dl>
<dt>1)</dt>
<dd>Skeletal Growth: GH
												stimulates skeletal growth in pediatric patients
												with growth failure due to a lack of adequate
												secretion of endogenous GH or secondary to chronic
												<span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and in patients with Turner
												syndrome. Skeletal growth is accomplished at the
												epiphyseal plates at the ends of a growing bone.
												Growth and metabolism of epiphyseal plate cells are
												directly stimulated by GH and one of its mediators,
												IGF‑I. Serum levels of IGF‑I are
												low in children and adolescents who are GH
												deficient, but increase during treatment with GH. In
												pediatric patients, new bone is formed at the
												epiphyses in response to GH and IGF‑I.
												This results in linear growth until these growth
												plates fuse at the end of puberty.</dd>
<dt>2)</dt>
<dd>Cell Growth: Treatment with
												hGH results in an increase in both the number and
												the size of skeletal muscle cells.</dd>
<dt>3)</dt>
<dd>Organ Growth: GH influences
												the size of internal organs, including kidneys, and
												increases red cell <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>. Treatment of
												hypophysectomized or genetic dwarf rats with GH
												results in organ growth that is proportional to the
												overall body growth. In normal rats subjected to
												nephrectomy‑induced <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>, GH promoted
												skeletal and body growth.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2"></a><p></p>
<h3><span class="Bold">B. Protein Metabolism</span></h3>
<p class="First">Linear growth is facilitated in part by
											GH‑stimulated protein synthesis. This is
											reflected by nitrogen retention as demonstrated by a
											decline in urinary nitrogen excretion and blood urea
											nitrogen during GH therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.3"></a><p></p>
<h3><span class="Bold">C. Carbohydrate Metabolism</span></h3>
<p class="First">GH is a modulator of carbohydrate metabolism. For
											example, patients with inadequate secretion of GH
											sometimes experience fasting <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> that is
											improved by treatment with GH. GH therapy may decrease
											insulin sensitivity. Untreated patients with chronic
											<span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and Turner syndrome have an
											increased incidence of <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span>.
											Administration of hGH to adults or children resulted in
											increases in serum fasting and postprandial insulin
											levels, more commonly in overweight or obese
											individuals. In addition, mean fasting and postprandial
											glucose and hemoglobin A<span class="Sub">1c</span> levels remained in
											the normal range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.4"></a><p></p>
<h3><span class="Bold">D. Lipid Metabolism</span></h3>
<p class="First">In GH‑deficient patients,
											administration of GH resulted in lipid mobilization,
											reduction in body fat stores, increased plasma fatty
											acids, and decreased plasma <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>
											levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.5"></a><p></p>
<h3><span class="Bold">E. Mineral Metabolism</span></h3>
<p class="First">The retention of total body potassium in response
											to GH administration apparently results from cellular
											growth. Serum levels of inorganic phosphorus may
											increase slightly in patients with inadequate secretion
											of endogenous GH, <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal insufficiency</span>, or
											patients with Turner syndrome during GH therapy due to
											metabolic activity associated with bone growth as well
											as increased tubular reabsorption of phosphate by the
											kidney. Serum calcium is not significantly altered in
											these patients. <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">Sodium retention</span> also occurs. Adults
											with childhood‑onset GH deficiency show low
											bone mineral density (BMD). GH therapy results in
											increases in serum alkaline phosphatase. (See <a href="#Laboratory_Tests">PRECAUTIONS: Laboratory
												Tests</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.6"></a><p></p>
<h3><span class="Bold">F. Connective Tissue
										Metabolism</span></h3>
<p class="First">GH stimulates the synthesis of chondroitin
											sulfate and collagen as well as the urinary excretion of
											hydroxyproline.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<h3>Subcutaneous Absorption</h3>
<p class="First">The absolute bioavailability of recombinant human
											growth hormone (rhGH) after subcutaneous administration
											in healthy adult males has been determined to be
											81±20%. The mean terminal
											t<span class="Sub">½</span> after subcutaneous
											administration is significantly longer than that seen
											after intravenous administration
											(2.1±0.43 hours vs.
											19.5±3.1 minutes) indicating that the
											subcutaneous absorption of the compound is slow and
											rate‑limiting.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">Animal studies with rhGH showed that GH localizes
											to highly perfused organs, particularly the liver and
											kidney. The volume of distribution at steady state for
											rhGH in healthy adult males is about 50 mL/kg
											body weight, approximating the serum volume.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Both the liver and kidney have been shown to be
											important metabolizing organs for GH. Animal studies
											suggest that the kidney is the dominant organ of
											clearance. GH is filtered at the glomerulus and
											reabsorbed in the proximal tubules. It is then cleaved
											within renal cells into its constituent amino acids,
											which return to the systemic circulation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.4"></a><p></p>
<h3>Elimination</h3>
<p class="First">The mean terminal t<span class="Sub">½</span> after
											intravenous administration of rhGH in healthy adult
											males is estimated to be
											19.5±3.1 minutes. Clearance of rhGH
											after intravenous administration in healthy adults and
											children is reported to be in the range of
											116–174 mL/hr/kg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.5"></a><p></p>
<h3>Bioequivalence of
										Formulations</h3>
<p class="First">Nutropin has been determined to be bioequivalent
											to Nutropin AQ<span class="Sup">®</span> [somatropin (rDNA
											origin) injection] based on the statistical evaluation
											of AUC and C<span class="Sub">max</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.6"></a><p></p>
<h3>SPECIAL POPULATIONS</h3>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.6.1"></a><p></p>
<h4>Pediatric</h4>
<p class="First">Available literature data suggest that
													rhGH clearances are similar in adults and
													children.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.6.2"></a><p></p>
<h4>Gender</h4>
<p class="First">No data are available for exogenously
													administered rhGH. Available data for methionyl
													recombinant GH, pituitary‑derived GH,
													and endogenous GH suggest no consistent
													gender‑based differences in GH
													clearance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.6.3"></a><p></p>
<h4>Geriatrics</h4>
<p class="First">Limited published data suggest that the
													plasma clearance and average
													steady‑state plasma concentration of
													rhGH may not be different between young and
													elderly patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.6.4"></a><p></p>
<h4>Race</h4>
<p class="First">Reported values for half‑lives
													for endogenous GH in normal adult black males
													are not different from observed values for
													normal adult white males. No data for other
													races are available.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.6.5"></a><p></p>
<h4>Growth Hormone
												Deficiency (GHD)</h4>
<p class="First">Reported values for clearance of rhGH in
													adults and children with GHD range
													138–245 mL/hr/kg and are
													similar to those observed in healthy adults and
													children. Mean terminal t<span class="Sub">½</span>
													values following intravenous and subcutaneous
													administration in adult and pediatric GHD
													patients are also similar to those observed in
													healthy adult males.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.6.6"></a><p></p>
<h4>Renal
												Insufficiency</h4>
<p class="First">Children and adults with chronic renal
													failure (CRF) and end‑stage renal
													disease (ESRD) tend to have decreased clearance
													compared to normals. In a study with six
													pediatric patients 7 to 11 years of age, the
													clearance of Nutropin was reduced by
													21.5% and 22.6% after the
													intravenous infusion and subcutaneous injection,
													respectively, of 0.05 mg/kg of Nutropin
													compared to normal healthy adults. Endogenous GH
													production may also increase in some individuals
													with ESRD. However, no rhGH accumulation has
													been reported in children with CRF or ESRD dosed
													with current regimens.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.6.7"></a><p></p>
<h4>Turner Syndrome</h4>
<p class="First">No pharmacokinetic data are available for
													exogenously administered rhGH. However, reported
													half‑lives, absorption, and
													elimination rates for endogenous GH in this
													population are similar to the ranges observed
													for normal subjects and GHD
													populations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.6.8"></a><p></p>
<h4>Hepatic
												Insufficiency</h4>
<p class="First">A reduction in rhGH clearance has been
													noted in patients with severe liver dysfunction.
													The clinical significance of this decrease is
													unknown.</p>
<table width="50%">
<caption><span>Summary of Nutropin Pharmacokinetic
														Parameters in Healthy Adult Males
														0.1 mg (approximately
														0.3 IU<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>)/kg
														SC</span></caption>
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<thead><tr class="First Last">
<th class="Lrule" align="center"></th>
<th align="center">C<span class="Sub">max</span> (µg/L)</th>
<th align="center">T<span class="Sub">max</span> (hr)</th>
<th align="center">t<span class="Sub">½</span> (hr)</th>
<th align="center">AUC<span class="Sub">0-∞</span>
																(µg ∙ hr/L)</th>
<th class="Rrule" align="center">CL/F<span class="Sub">sc</span>
																(mL/[hr ∙ kg])</th>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="6">Abbreviations:</td></tr>
<tr><td align="left" colspan="6">C<span class="Sub">max</span>=maximum
																concentration</td></tr>
<tr><td align="left" colspan="6">t<span class="Sub">½</span>=half‑life</td></tr>
<tr><td align="left" colspan="6">AUC<span class="Sub">0-∞</span>=area
																under the curve</td></tr>
<tr><td align="left" colspan="6">CL/F<span class="Sub">sc</span>=systemic
																clearance</td></tr>
<tr><td align="left" colspan="6">F<span class="Sub">sc</span>=subcutaneous
																bioavailability (not
																determined)</td></tr>
<tr class="Last"><td align="left" colspan="6">CV%=coefficient of variation in %;
																SC=subcutaneous</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Based on
															current International Standard of
															3 IU=1 mg</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>n=36</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="center">MEAN<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td align="center">67.2</td>
<td align="center">6.2</td>
<td align="center">2.1</td>
<td align="center">643</td>
<td class="Rrule" align="center">158</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">CV%</td>
<td align="center">29</td>
<td align="center">37</td>
<td align="center">20</td>
<td align="center">12</td>
<td class="Rrule" align="center">12</td>
</tr>
</tbody>
</table>
<p class="Bold"><span class="ParagraphCaption">Single Dose Mean Growth Hormone Concentrations in Healthy Adult Males</span></p>
<div class="Figure"><img alt="Single Dose Mean Growth Hormone Concentrations in Healthy Adult Males" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e6574a25-1ad5-4946-b750-501ce745574f&amp;name=nutropin-image01.jpg"></div>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-3"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4266035" conceptname="Growth hormone deficiency">Growth Hormone Deficiency</span> (GHD)
								in Pubertal Patients</h2>
<p class="First">One open‑label, multicenter, randomized
									clinical trial of two dosages of Nutropin was performed
									in pubertal patients with GHD.
									Ninety‑seven patients (mean age
									13.9 years, 83 male, 14 female)
									currently being treated with approximately 0.3 mg/kg/wk
									of GH were randomized to 0.3 mg/kg/wk or
									0.7 mg/kg/wk Nutropin doses. All patients were already
									in puberty (Tanner stage ≥2) and had bone ages
									≤14 years in males or
									≤12 years in females. Mean baseline height
									standard deviation (SD) score was –1.3.</p>
<p>The mean last measured height in all 97 patients
									after a mean duration of 2.7±1.2 years, by
									analysis of covariance (ANCOVA) adjusting for baseline height,
									is shown below.</p>
<table width="60%">
<caption><span>Last Measured Height<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> by Sex and Nutropin Dose</span></caption>
<col align="right">
<col align="center">
<col align="center">
<col align="center">
<col align="center" width="20%">
<thead>
<tr class="First">
<th class="Lrule" align="right"></th>
<th align="center"></th>
<th align="center" colspan="2" valign="bottom">Last Measured
												Height<a href="#footnote-3" class="Sup">*</a> (cm)</th>
<th class="Botrule Rrule" align="center" rowspan="2" valign="bottom">Height Difference Between
												Groups (cm)</th>
</tr>
<tr class="Botrule">
<th class="Lrule" align="right"></th>
<th align="center" valign="bottom">Age (yr)</th>
<th align="center" valign="bottom">0.3 mg/kg/wk</th>
<th align="center" valign="bottom">0.7 mg/kg/wk</th>
</tr>
<tr class="Last">
<th class="Lrule" align="right"></th>
<th align="center" valign="bottom">Mean±SD<br>(range)</th>
<th align="center" valign="bottom">Mean±SD</th>
<th align="center" valign="bottom">Mean±SD</th>
<th class="Rrule" align="center" valign="bottom">Mean±SE</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Adjusted
										for baseline height</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="right" valign="top"><span class="Bold">Male</span></td>
<td align="center" valign="top">17.2±1.3<br>(13.6 to 19.4)</td>
<td align="center" valign="top">170.9±7.9<br>(n=42)</td>
<td align="center" valign="top">174.5±7.9<br>(n=41)</td>
<td class="Rrule" align="center" valign="top">3.6±1.7</td>
</tr>
<tr class="Last">
<td class="Lrule" align="right"><span class="Bold">Female</span></td>
<td align="center">15.8±1.8<br>(11.9 to 19.3)</td>
<td align="center">154.7±6.3<br>(n=7)</td>
<td align="center">157.6±6.3<br>(n=7)</td>
<td class="Rrule" align="center">2.9±3.4</td>
</tr>
</tbody>
</table>
<p>The mean height SD score at last measured height (n=97)
									was –0.7±1.0 in the 0.3 mg/kg/wk
									group and –0.1± 1.2 in the
									0.7 mg/kg/wk group. For patients completing 3.5 or more
									years (mean 4.1 years) of Nutropin treatment
									(15/49 patients in the 0.3 mg/kg/wk group and
									16/48 patients in the 0.7 mg/kg/wk group), the
									mean last measured height was 166.1±8.0 cm in
									the 0.3 mg/kg/wk group and
									171.8±7.1 cm in the 0.7 mg/kg/wk
									group, adjusting for baseline height and sex.</p>
<p>The mean change in bone age was approximately
									one year for each year in the study in both dose
									groups. Patients with baseline height SD scores above
									–1.0 were able to attain normal adult heights with the
									0.3 mg/kg/wk dose of Nutropin (mean height SD score at
									near‑adult height=–0.1, n=15).</p>
<p>Thirty‑one patients had bone mineral
									density (BMD) determined by dual energy x‑ray
									absorptiometry (DEXA) scans at study conclusion. The two dose
									groups did not differ significantly in mean SD score for total
									body BMD (–0.9±1.9 in the
									0.3 mg/kg/wk group
									vs. –0.8±1.2 in the
									0.7 mg/kg/wk group, n=20) or lumbar spine BMD
									(–1.0±1.0 in the 0.3 mg/kg/wk group
									vs. –0.2±1.7 in the 0.7 mg/kg/wk
									group, n=21).</p>
<p>Over a mean duration of 2.7 years, patients in
									the 0.7 mg/kg/wk group were more likely to have
									IGF‑I values above the normal range than patients in
									the 0.3 mg/kg/wk group (27.7% vs. 9.0%
									of IGF‑I measurements for individual patients). The
									clinical significance of elevated IGF‑I values is
									unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Effects of Nutropin on Growth
								Failure Due to <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">Chronic Renal Insufficiency</span> (CRI)</h2>
<p class="First">Two multicenter, randomized, controlled clinical trials
									were conducted to determine whether treatment with Nutropin
									prior to renal transplantation in patients with chronic renal
									insufficiency could improve their growth rates and height
									deficits. One study was a double‑blind,
									placebo‑controlled trial and the other was an
									open‑label, randomized trial. The dose of Nutropin in
									both controlled studies was 0.05 mg/kg/day
									(0.35 mg/kg/week) administered daily by subcutaneous
									injection. Combining the data from those patients completing
									two years in the two controlled studies results in
									62 patients treated with Nutropin and
									28 patients in the control groups (either
									placebo‑treated or untreated). The mean first year
									growth rate was 10.8 cm/yr for
									Nutropin‑treated patients, compared with a mean growth
									rate of 6.5 cm/yr for placebo/untreated controls
									(p&lt;0.00005). The mean second year growth rate was
									7.8 cm/yr for the Nutropin‑treated group,
									compared with 5.5 cm/yr for controls
									(p&lt;0.00005). There was a significant increase in mean
									height standard deviation (SD) score in the Nutropin group
									(−2.9 at baseline to −1.5 at
									Month 24, n=62) but no significant change in the
									controls (−2.8 at baseline to −2.9 at
									Month 24, n=28). The mean third year growth rate of
									7.6 cm/yr in the Nutropin‑treated patients
									(n=27) suggests that Nutropin stimulates growth beyond
									two years. However, there are no control data for the
									third year because control patients crossed over to Nutropin
									treatment after two years of participation. The gains
									in height were accompanied by appropriate advancement of
									skeletal age. These data demonstrate that Nutropin therapy
									improves growth rate and corrects the acquired height deficit
									associated with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2>Post-Transplant Growth</h2>
<p class="First">The North American Pediatric Renal Transplant Cooperative
									Study (NAPRTCS) has reported data for growth
									post‑transplant in children who did not receive GH
									prior to transplantation as well as children who did receive
									Nutropin during the clinical trials prior to transplantation.
									The average change in height SD score during the initial two
									years post transplant was 0.15 for the 2391 patients who did not
									receive GH pre-transplant and 0.28 for the 57 patients who did
									(J Pediatr. 2000;136:376-382). For patients who were followed
									for 5 years post-transplant, the corresponding changes in height
									SD score were also similar between groups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4"></a><p></p>
<h2>Turner Syndrome</h2>
<p class="First">One long‑term, randomized,
									open‑label, multicenter, concurrently controlled
									study, two long‑term, open‑label,
									multicenter, historically controlled studies, and one
									long‑term, randomized, dose‑response study
									were conducted to evaluate the efficacy of GH for the treatment
									of girls with <span class="product-label-link" type="condition" conceptid="440076" conceptname="Short stature disorder">short stature</span> due to Turner syndrome.</p>
<p>In the randomized study GDCT, comparing
									GH‑treated patients to a concurrent control group who
									received no GH, the GH‑treated patients who received a
									dose of 0.3 mg/kg/week given 6 times per week
									from a mean age of 11.7 years for a mean duration of
									4.7 years attained a mean near final height of
									146.0 cm (n=27) as compared to the control group who
									attained a near final height of 142.1 cm (n=19). By
									analysis of covariance, the effect of GH therapy was a mean
									height increase of 5.4 cm (p=0.001).</p>
<p>In two of the studies (85‑023 and
									85‑044), the effect of long‑term GH
									treatment (0.375 mg/kg/week given either
									3 times per week or daily) on adult height was
									determined by comparing adult heights in the treated patients
									with those of age‑matched historical controls with
									Turner syndrome who never received any
									growth‑promoting therapy. In
									Study 85‑023, estrogen treatment was delayed
									until patients were at least age 14. GH therapy resulted in a
									mean adult height gain of 7.4 cm (mean duration of GH
									therapy of 7.6 years) vs. matched historical controls
									by analysis of covariance.</p>
<p>In Study 85‑044, patients treated with
									early GH therapy were randomized to receive
									estrogen‑replacement therapy (conjugated estrogens,
									0.3 mg escalating to 0.625 mg daily) at either
									age 12 or 15 years. Compared with matched historical
									controls, early GH therapy (mean duration of GH therapy
									5.6 years) combined with estrogen replacement at age
									12 years resulted in an adult height gain of
									5.9 cm (n=26), whereas girls who initiated estrogen at
									age 15 years (mean duration of GH therapy
									6.1 years) had a mean adult height gain of
									8.3 cm (n=29). Patients who initiated GH therapy after
									age 11 (mean age 12.7 years; mean duration of GH
									therapy 3.8 years) had a mean adult height gain of
									5.0 cm (n=51).</p>
<p>Thus, in both studies, 85‑023 and
									85‑044, the greatest improvement in adult height was
									observed in patients who received early GH treatment and
									estrogen after age 14 years.</p>
<p>In a randomized, blinded, dose‑response study,
									GDCI, patients were treated from a mean age of
									11.1 years for a mean duration of 5.3 years
									with a weekly dose of either 0.27 mg/kg or
									0.36 mg/kg administered 3 or 6 times weekly.
									The mean near final height of patients receiving growth hormone
									was 148.7 cm (n=31). This represents a mean gain in
									adult height of approximately 5 cm compared with
									previous observations of untreated Turner syndrome girls.</p>
<p>In these studies, Turner syndrome patients (n=181)
									treated to final adult height achieved statistically significant
									average estimated adult height gains ranging from
									5.0–8.3 cm.</p>
<table width="80%">
<col align="left">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<thead><tr class="First Last">
<th class="Lrule" align="left" valign="bottom">Study/Group</th>
<th align="center" valign="bottom">Study Design<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</th>
<th align="center" valign="bottom">N at Adult Height</th>
<th align="center" valign="bottom">GH Age (yr)</th>
<th align="center" valign="bottom">Estrogen Age (yr)</th>
<th align="center" valign="bottom">GH Duration (yr)</th>
<th class="Rrule" align="center" valign="bottom">Adult Height Gain
												(cm)<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>RCT:
												randomized controlled trial; MHT: matched
												historical controlled trial;<br>RDT: randomized
												dose‑response trial</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>Analysis of covariance vs.
													controls</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>A = GH age &lt;11 yr, estrogen age 15
												yr<br>B = GH age &lt;11 yr, estrogen age 12
												yr<br>C = GH age &gt;11 yr, estrogen at
												Month 12 </dd>
<dt><a name="footnote-7" href="#footnote-reference-7">§</a></dt>
<dd>Compared with
												historical data</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">GDCT</td>
<td align="center">RCT</td>
<td align="center">27</td>
<td align="center">11.7</td>
<td align="center">13</td>
<td align="center">4.7</td>
<td class="Rrule" align="center">5.4</td>
</tr>
<tr>
<td class="Lrule" align="left">85-023</td>
<td align="center">MHT</td>
<td align="center">17</td>
<td align="center">9.1</td>
<td align="center">15.2</td>
<td align="center">7.6</td>
<td class="Rrule" align="center">7.4</td>
</tr>
<tr>
<td class="Lrule" align="left">85-044: A<a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a>
</td>
<td align="center">MHT</td>
<td align="center">29</td>
<td align="center">9.4</td>
<td align="center">15.0</td>
<td align="center">6.1</td>
<td class="Rrule" align="center">8.3</td>
</tr>
<tr>
<td class="Lrule" align="left"> B<a href="#footnote-6" class="Sup">‡</a>
</td>
<td align="center"></td>
<td align="center">26</td>
<td align="center">9.6</td>
<td align="center">12.3</td>
<td align="center">5.6</td>
<td class="Rrule" align="center">5.9</td>
</tr>
<tr>
<td class="Lrule" align="left"> C<a href="#footnote-6" class="Sup">‡</a>
</td>
<td align="center"></td>
<td align="center">51</td>
<td align="center">12.7</td>
<td align="center">13.7</td>
<td align="center">3.8</td>
<td class="Rrule" align="center">5.0</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">GDCI</td>
<td align="center">RDT</td>
<td align="center">31</td>
<td align="center">11.1</td>
<td align="center">8–13.5</td>
<td align="center">5.3</td>
<td class="Rrule" align="center">~5<a name="footnote-reference-7" href="#footnote-7" class="Sup">§</a>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5"></a><p></p>
<h2>Idiopathic <span class="product-label-link" type="condition" conceptid="440076" conceptname="Short stature disorder">Short Stature</span> (ISS)</h2>
<p class="First"> A long‑term, open‑label, multicenter
									study (86‑053) was conducted to examine the safety and
									efficacy of Nutropin in pediatric patients with idiopathic short
									stature, also called non‑GH deficient <span class="product-label-link" type="condition" conceptid="440076" conceptname="Short stature disorder">short stature</span>.
									For the first year, 122 pre‑pubertal subjects
									over the age of 5 years with stimulated serum
									GH≥10 ng/mL were randomized into
									two treatment groups of approximately equal size; one
									group was treated with Nutropin 0.3 mg/kg weekly
									divided into three doses per week (TIW) and the other
									group served as untreated controls. For the second and
									subsequent years of the study, all subjects were
									re‑randomized to receive the same total weekly dose of
									Nutropin (0.3 mg/kg weekly) administered either daily
									or TIW. Treatment with Nutropin was continued until a subject’s
									bone age was &gt;15.0 years (boys) or
									&gt;14.0 years (girls) and the growth rate was
									&lt;2 cm/yr, after which subjects were followed
									until adult height was achieved. The mean baseline values were:
									height SD score –2.8, IGF‑I SD score
									–0.9, age 9.4 years, bone age
									7.8 years, growth rate 4.4 cm/yr,
									mid‑parental target height SD score –0.7,
									and Bayley‑Pinneau predicted adult height SD score
									–2.3. Nearly all subjects had predicted adult height
									that was less than mid‑parental target height. </p>
<p> During the one‑year controlled phase of the
									study, the mean height velocity increased by
									0.5±1.8 cm (mean±SD) in the
									no‑treatment control group and by
									3.1±1.7 cm in the Nutropin group
									(p&lt;0.0001). For the same period of treatment the mean
									height SD score increased by 0.4±0.2 and remained
									unchanged (0.0±0.2) in the control group
									(p&lt;0.001). </p>
<p> Of the 118 subjects who were treated with
									Nutropin in Study 86‑053, 83 (70%) reached
									near‑adult height (hereafter called adult height)
									after 2–10 years of Nutropin therapy. Their
									last measured height, including post‑treatment
									follow‑up, was obtained at a mean age of
									18.3 years in males and 17.3 years in females.
									The mean duration of therapy was 6.2 and 5.5 years,
									respectively. Adult height was greater than pretreatment
									predicted adult height in 49 of 60 males (82%) and 19
									of 23 females (83%). The mean difference between adult
									height and pretreatment predicted adult height was
									5.2 cm (2.0 inches) in males and
									6.0 cm (2.4 inches) in females
									(p&lt;0.0001 for both). The table (below) summarizes the
									efficacy data. </p>
<table width="50%">
<caption><span>Long‑Term Efficacy in Study 86‑053
										(Mean±SD) </span></caption>
<col align="left">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<thead><tr class="First Last">
<th class="Lrule" align="center" valign="bottom">Characteristic</th>
<th align="center" valign="bottom">Males(n=60)</th>
<th class="Rrule" align="center" valign="bottom">Females(n=23)</th>
</tr></thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>
												p&lt;0.0001 versus zero.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Adult height (cm)</td>
<td align="center">166.3±5.8</td>
<td class="Rrule" align="center">153.1±4.8</td>
</tr>
<tr>
<td class="Lrule" align="left">Pretreatment predicted adult
												height (cm)</td>
<td align="center">161.1±5.5</td>
<td class="Rrule" align="center">147.1±5.1</td>
</tr>
<tr>
<td class="Lrule" align="left">Adult height minus pretreatment
												predicted<br>adult height (cm)</td>
<td align="center">+5.2±5.0 <a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a>
</td>
<td class="Rrule" align="center">+6.0±5.0
												<a href="#footnote-8" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Lrule" align="left">Adult height SD score</td>
<td align="center">–1.5±0.8</td>
<td class="Rrule" align="center">–1.6±0.7</td>
</tr>
<tr>
<td class="Lrule" align="left">Pretreatment predicted adult
												height SD score</td>
<td align="center">–2.2±0.8</td>
<td class="Rrule" align="center">–2.5±0.8</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Adult height minus pretreatment
												predicted<br>adult height SD score</td>
<td align="center">+0.7±0.7 <a href="#footnote-8" class="Sup">*</a>
</td>
<td class="Rrule" align="center">+0.9±0.8
												<a href="#footnote-8" class="Sup">*</a>
</td>
</tr>
</tbody>
</table>
<p> Nutropin therapy resulted in an increase in mean
									IGF‑I SD score from –0.9±1.0 to
									–0.2±0.9 in Treatment Year 1. During
									continued treatment, mean IGF‑I levels remained close
									to the normal mean. IGF‑I SD scores above +2
									occurred sporadically in 14 subjects. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.6"></a><p></p>
<h2>Adult <span class="product-label-link" type="condition" conceptid="4266035" conceptname="Growth hormone deficiency">Growth Hormone Deficiency</span>
								(GHD)</h2>
<p class="First">Two multicenter, double‑blind,
									placebo‑controlled clinical trials were conducted
									using Nutropin [somatropin (rDNA origin) for injection] in
									GH‑deficient adults. One study was conducted in
									subjects with adult‑onset GHD, mean age
									48.3 years, n=166, at doses of 0.0125 or
									0.00625 mg/kg/day; doses of 0.025 mg/kg/day
									were not tolerated in these subjects. A second study was
									conducted in previously treated subjects with
									childhood‑onset GHD, mean age 23.8 years,
									n=64, at randomly assigned doses of 0.025 or
									0.0125 mg/kg/day. The studies were designed to assess
									the effects of replacement therapy with GH on body composition.</p>
<p>Significant changes from baseline to Month 12 of
									treatment in body composition (i.e., total body % fat
									<span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>, trunk % fat <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>, and total body % lean
									<span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> by DEXA scan) were seen in all Nutropin groups in both
									studies (p&lt;0.0001 for change from baseline and vs.
									placebo), whereas no statistically significant changes were seen
									in either of the placebo groups. In the adult‑onset
									study, the Nutropin group improved mean total body fat from
									35.0% to 31.5%, mean trunk fat from
									33.9% to 29.5%, and mean lean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> from
									62.2% to 65.7%, whereas the placebo group had
									mean changes of 0.2% or less (p=not significant). Due to
									the possible effect of GH‑induced <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> on
									DEXA measurements of lean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>, DEXA scans were repeated
									approximately 3 weeks after completion of therapy; mean
									% lean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> in the Nutropin group was
									65.0%, a change of 2.8% from baseline, compared
									with a change of 0.4% in the placebo group
									(p&lt;0.0001 between groups).</p>
<p>In the childhood‑onset study, the
									high‑dose Nutropin group improved mean total body fat
									from 38.4% to 32.1%, mean trunk fat from
									36.7% to 29.0%, and mean lean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> from
									59.1% to 65.5%; the low‑dose Nutropin
									group improved mean total body fat from 37.1% to
									31.3%, mean trunk fat from 37.9% to
									30.6%, and mean lean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> from 60.0% to
									66.0%; the placebo group had mean changes of
									0.6% or less (p=not significant).</p>
<table width="95%">
<caption><span>Mean Changes from Baseline to Month 12 in
										Proportion of Fat and Lean by DEXA for Studies M0431g and
										M0381g (Adult‑onset and Childhood‑onset
										GHD, respectively)</span></caption>
<col align="left" width="30%">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<thead>
<tr class="First">
<th class="Lrule" align="left"></th>
<th align="center" colspan="3">M0431g</th>
<th class="Botrule Rrule" align="center" colspan="4">M0381g</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule" align="center" valign="bottom">Proportion</th>
<th class="Toprule" align="center" valign="bottom">Placebo<br>(n=62)</th>
<th class="Toprule" align="center" valign="bottom">Nutropin<br>(n=63)</th>
<th class="Toprule" align="center" valign="bottom">Between-Groups<br>t‑test
												p‑value</th>
<th align="center" valign="bottom">Placebo<br> (n=13)</th>
<th align="center" valign="bottom">Nutropin<br> 0.0125
												mg/kg/day<br>(n=15)</th>
<th align="center" valign="bottom">Nutropin<br> 0.025
												mg/kg/day<br>(n=15)</th>
<th class="Rrule" align="center" valign="bottom">Placebo vs. Pooled
												Nutropin<br> t‑test
												p‑value</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="Bold">Total body percent
													fat</span></td>
<td class="Lrule" align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td class="Lrule" align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">Baseline</td>
<td class="Lrule" align="center">36.8</td>
<td align="center">35.0</td>
<td align="center">0.38</td>
<td class="Lrule" align="center">35.0</td>
<td align="center">37.1</td>
<td align="center">38.4</td>
<td class="Rrule" align="center">0.45</td>
</tr>
<tr>
<td class="Lrule" align="left">Month 12</td>
<td class="Lrule" align="center">36.8</td>
<td align="center">31.5</td>
<td align="center"></td>
<td class="Lrule" align="center">35.2</td>
<td align="center">31.3</td>
<td align="center">32.1</td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">Baseline to Month 12
												change</td>
<td class="Lrule" align="center"><span class="Bold">−0.1</span></td>
<td align="center"><span class="Bold">−3.6</span></td>
<td align="center">&lt;0.0001</td>
<td class="Lrule" align="center"><span class="Bold">+ 0.2</span></td>
<td align="center"><span class="Bold">−5.8</span></td>
<td align="center"><span class="Bold">−6.3</span></td>
<td class="Rrule" align="center">&lt;0.0001</td>
</tr>
<tr>
<td class="Lrule" align="left">Post-washout</td>
<td class="Lrule" align="center">36.4</td>
<td align="center">32.2</td>
<td align="center"></td>
<td class="Lrule" align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">Baseline to post-washout change</td>
<td class="Lrule" align="center"><span class="Bold">−0.4</span></td>
<td align="center"><span class="Bold">−2.8</span></td>
<td align="center">&lt;0.0001</td>
<td class="Lrule" align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Trunk percent
													fat</span></td>
<td class="Lrule" align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td class="Lrule" align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">Baseline</td>
<td class="Lrule" align="center">35.3</td>
<td align="center">33.9</td>
<td align="center">0.50</td>
<td class="Lrule" align="center">32.5</td>
<td align="center">37.9</td>
<td align="center">36.7</td>
<td class="Rrule" align="center">0.23</td>
</tr>
<tr>
<td class="Lrule" align="left">Month 12</td>
<td class="Lrule" align="center">35.4</td>
<td align="center">29.5</td>
<td align="center"></td>
<td class="Lrule" align="center">33.1</td>
<td align="center">30.6</td>
<td align="center">29.0</td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">Baseline to Month 12
												change</td>
<td class="Lrule" align="center"><span class="Bold">0.0</span></td>
<td align="center"><span class="Bold">−4.3</span></td>
<td align="center">&lt;0.0001</td>
<td class="Lrule" align="center"><span class="Bold">+ 0.6</span></td>
<td align="center"><span class="Bold">−7.3</span></td>
<td align="center"><span class="Bold">−7.6</span></td>
<td class="Rrule" align="center">&lt;0.0001</td>
</tr>
<tr>
<td class="Lrule" align="left">Post-washout</td>
<td class="Lrule" align="center">34.9</td>
<td align="center">30.5</td>
<td align="center"></td>
<td class="Lrule" align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">Baseline to post-washout change</td>
<td class="Lrule" align="center"><span class="Bold">−0.3</span></td>
<td align="center"><span class="Bold">−3.4</span></td>
<td align="center"></td>
<td class="Lrule" align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Total body percent
													lean</span></td>
<td class="Lrule" align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td class="Lrule" align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">Baseline</td>
<td class="Lrule" align="center">60.4</td>
<td align="center">62.2</td>
<td align="center">0.37</td>
<td class="Lrule" align="center">62.0</td>
<td align="center">60.0</td>
<td align="center">59.1</td>
<td class="Rrule" align="center">0.48</td>
</tr>
<tr>
<td class="Lrule" align="left">Month 12</td>
<td class="Lrule" align="center">60.5</td>
<td align="center">65.7</td>
<td align="center"></td>
<td class="Lrule" align="center">61.8</td>
<td align="center">66.0</td>
<td align="center">65.5</td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">Baseline to Month 12
												change</td>
<td class="Lrule" align="center"><span class="Bold">+ 0.2</span></td>
<td align="center"><span class="Bold">+ 3.6</span></td>
<td align="center">&lt;0.0001</td>
<td class="Lrule" align="center"><span class="Bold">−0.2</span></td>
<td align="center"><span class="Bold">+ 6.0</span></td>
<td align="center"><span class="Bold">+ 6.4</span></td>
<td class="Rrule" align="center">&lt;0.0001</td>
</tr>
<tr>
<td class="Lrule" align="left">Post-washout</td>
<td class="Lrule" align="center">60.9</td>
<td align="center">65.0</td>
<td align="center"></td>
<td class="Lrule" align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Baseline to post-washout change</td>
<td class="Lrule" align="center"><span class="Bold">+ 0.4</span></td>
<td align="center"><span class="Bold">+ 2.8</span></td>
<td align="center">&lt;0.0001</td>
<td class="Lrule" align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
<p>In the adult‑onset study, significant decreases
									from baseline to Month 12 in LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and
									LDL:HDL ratio were seen in the Nutropin group compared to the
									placebo group, p&lt;0.02; there were no statistically
									significant between‑group differences in change from
									baseline to Month 12 in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, HDL
									<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, or triglycerides. In the childhood‑onset
									study, significant decreases from baseline to Month 12
									in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and LDL:HDL ratio were
									seen in the high‑dose Nutropin group only, compared to
									the placebo group, p&lt;0.05. There were no statistically
									significant between‑group differences in HDL
									<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or triglycerides from baseline to Month 12.</p>
<p>In the childhood‑onset study, 55% of
									the patients had decreased spine bone mineral density (BMD)
									(z‑score &lt;–1) at baseline. The
									administration of Nutropin (n=16) (0.025 mg/kg/day) for
									two years resulted in increased spine BMD from baseline
									when compared to placebo (n=13) (4.6% vs. 1.0%,
									respectively, p&lt;0.03); a transient decrease in spine BMD
									was seen at six months in the
									Nutropin‑treated patients.
									Thirty‑five percent of subjects treated with
									this dose had supraphysiological levels of IGF‑I at
									some point during the study, which may carry unknown risks. No
									significant improvement in total body BMD was found when
									compared to placebo. A lower GH dose (0.0125 mg/kg/day)
									did not show significant increments in either of these bone
									parameters when compared to placebo. No statistically
									significant effects on BMD were seen in the
									adult‑onset study where patients received GH
									(0.0125 mg/kg/day) for one year. </p>
<p>Muscle strength, physical endurance, and quality of life
									measurements were not markedly abnormal at baseline, and no
									statistically significant effects of Nutropin therapy were
									observed in the two studies.</p>
<p>A subsequent 32‑week, multicenter,
									open‑label, controlled clinical trial (M2378g) was
									conducted using Nutropin AQ, Nutropin Depot, or no treatment in
									adults with both adult‑onset and
									childhood‑onset GHD. Subjects were randomized into the
									three groups to evaluate effects on body composition,
									including change in visceral adipose tissue (VAT) as determined
									by computed tomography (CT) scan.</p>
<p>For subjects evaluable for change in VAT in the Nutropin
									AQ (n=44) and untreated (n=19) groups, the mean age was
									46.2 years and 78% had adult‑onset
									GHD. Subjects in the Nutropin AQ group were treated at doses up
									to 0.012 mg/kg per day in women (all of whom received
									estrogen replacement therapy) and men under age
									35 years, and up to 0.006 mg/kg per day in men
									over age 35 years.</p>
<p>The mean absolute change in VAT from baseline to
									Week 32 was –10.7 cm<span class="Sup">2</span> in
									the Nutropin AQ group and +8.4 cm<span class="Sup">2</span>
									in the untreated group (p=0.013 between groups). There was a
									6.7% VAT loss in the Nutropin AQ group (mean percent
									change from baseline to Week 32) compared with a
									7.5% increase in the untreated group (p=0.012 between
									groups). The effect of reducing VAT in adult GHD patients with
									Nutropin AQ on long‑term cardiovascular morbidity and
									mortality has not been determined.</p>
<table width="65%">
<caption><span>Visceral Adipose Tissue by Computed Tomography Scan:
										Percent Change and Absolute Change from Baseline to Week 32
										in Study M2378g</span></caption>
<col align="left">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<thead><tr class="First Last">
<th class="Lrule" align="center" valign="bottom"></th>
<th align="center" valign="bottom">Nutropin<br>AQ<br>(n = 44)</th>
<th align="center" valign="bottom">Untreated<br>(n = 19)</th>
<th align="center" valign="bottom">Treatment<br>Difference<br>(adjusted mean)</th>
<th class="Rrule" align="center" valign="bottom">p-value</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>ANCOVA using baseline VAT as a
												covariate</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Baseline VAT
												(cm<span class="Sup">2</span>)(mean)</td>
<td align="center">126.2</td>
<td align="center">123.3</td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Change in VAT
												(cm<span class="Sup">2</span>)(adjusted mean)</td>
<td class="Toprule" align="center">-10.7</td>
<td class="Toprule" align="center">+8.4</td>
<td class="Toprule" align="center">-19.1</td>
<td class="Rrule Toprule" align="center">0.013<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule Toprule" align="left">Percent change in VAT
												(adjusted mean)</td>
<td class="Toprule" align="center">-6.7</td>
<td class="Toprule" align="center">+7.5</td>
<td class="Toprule" align="center">-14.2</td>
<td class="Rrule Toprule" align="center">0.012<a href="#footnote-9" class="Sup">*</a>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="indications_and_usage"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First">Nutropin<span class="Sup">®</span> [somatropin (rDNA origin)
									for injection] is indicated for the long‑term
									treatment of growth failure due to a lack of adequate endogenous
									GH secretion.</p>
<p>Nutropin<span class="Sup">®</span> [somatropin (rDNA origin)
									for injection] is also indicated for the treatment of growth
									failure associated with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal insufficiency</span> up to the
									time of renal transplantation. Nutropin therapy should be used
									in conjunction with optimal management of chronic renal
									insufficiency.</p>
<p>Nutropin<span class="Sup">®</span> [somatropin (rDNA origin)
									for injection] is also indicated for the long‑term
									treatment of <span class="product-label-link" type="condition" conceptid="440076" conceptname="Short stature disorder">short stature</span> associated with Turner syndrome.</p>
<p>Nutropin<span class="Sup">®</span> [somatropin (rDNA origin)
									for injection] is also indicated for the long‑term
									treatment of idiopathic <span class="product-label-link" type="condition" conceptid="440076" conceptname="Short stature disorder">short stature</span>, also called
									non‑growth hormone‑deficient <span class="product-label-link" type="condition" conceptid="440076" conceptname="Short stature disorder">short stature</span>,
									defined by height SDS ≤–2.25, and associated
									with growth rates unlikely to permit attainment of adult height
									in the normal range, in pediatric patients whose epiphyses are
									not closed and for whom diagnostic evaluation excludes other
									causes associated with <span class="product-label-link" type="condition" conceptid="440076" conceptname="Short stature disorder">short stature</span> that should be observed or
									treated by other means.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>Adult Patients</h2>
<p class="First">Nutropin<span class="Sup">®</span> [somatropin (rDNA origin)
									for injection] is indicated for the replacement of endogenous
									growth hormone in adults with <span class="product-label-link" type="condition" conceptid="4266035" conceptname="Growth hormone deficiency">growth hormone deficiency</span> who meet
									either of the following two criteria:</p>
<p>Adult Onset: Patients who have adult growth hormone
									deficiency either alone or associated with multiple hormone
									deficiencies (<span class="product-label-link" type="condition" conceptid="4254542" conceptname="Hypopituitarism">hypopituitarism</span>) as a result of pituitary disease,
									hypothalamic disease, surgery, radiation therapy, or <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>; or</p>
<p>Childhood Onset: Patients who were growth hormone
									deficient during childhood as a result of congenital, genetic,
									acquired, or idiopathic causes.</p>
<p>In general, confirmation of the diagnosis of adult growth
									hormone deficiency in <span class="Underline">both</span> groups usually requires an appropriate growth
									hormone stimulation test. However, confirmatory growth hormone
									stimulation testing may not be required in patients with
									congenital/genetic <span class="product-label-link" type="condition" conceptid="4266035" conceptname="Growth hormone deficiency">growth hormone deficiency</span> or multiple
									pituitary hormone deficiencies due to organic
									disease.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Contraindications"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Somatropin should not be used for growth promotion in pediatric
							patients with closed epiphyses.</p>
<p>Somatropin is contraindicated in patients with active
							proliferative or severe non-proliferative <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">diabetic retinopathy</span>.</p>
<p>In general, somatropin is contraindicated in the presence of
							active malignancy. Any pre‑existing malignancy should be
							inactive and its treatment complete prior to instituting therapy with
							somatropin. Somatropin should be discontinued if there is evidence of
							recurrent activity. Since <span class="product-label-link" type="condition" conceptid="4266035" conceptname="Growth hormone deficiency">growth hormone deficiency</span> may be an early sign
							of the presence of a pituitary tumor (or, rarely, other <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumors</span>),
							the presence of such tumors should be ruled out prior to initiation of
							treatment. Somatropin should not be used in patients with any evidence
							of progression or recurrence of an underlying intracranial tumor.</p>
<p>Somatropin should not be used to treat patients with acute
							critical illness due to complications following open heart surgery,
							abdominal surgery or multiple accidental <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, or those with acute
							<span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>. Two placebo‑controlled clinical
							trials in non‑growth hormone‑deficient adult
							patients (n=522) with these conditions in intensive care units revealed
							a significant increase in mortality (41.9% vs. 19.3%)
							among somatropin‑treated patients (doses
							5.3–8 mg/day) compared to those receiving placebo
							(see <a href="#Warnings">WARNINGS</a>).</p>
<p>Somatropin is contraindicated in patients with
							Prader‑Willi syndrome who are severely obese or have severe
							respiratory impairment (see <a href="#Warnings">WARNINGS</a>). Unless patients with Prader‑Willi
							syndrome also have a diagnosis of <span class="product-label-link" type="condition" conceptid="4266035" conceptname="Growth hormone deficiency">growth hormone deficiency</span>, Nutropin is
							not indicated for the long‑term treatment of pediatric
							patients who have growth failure due to genetically confirmed
							Prader‑Willi syndrome.</p>
<p>Nutropin, when reconstituted with Bacteriostatic Water for
							Injection, USP (benzyl alcohol preserved), should not be used in
							patients with a known sensitivity to benzyl alcohol. For use in newborns
							see <a href="#Warnings">WARNINGS</a>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">See <a href="#Contraindications">CONTRAINDICATIONS</a> for information on increased mortality in
							patients with acute critical illness due to complications following open
							heart surgery, abdominal surgery or multiple accidental <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, or those
							with <span class="product-label-link" type="condition" conceptid="319049" conceptname="Acute respiratory failure">acute respiratory failure</span>. The safety of continuing somatropin
							treatment in patients receiving replacement doses for approved
							indications who concurrently develop these illnesses has not been
							established. Therefore, the potential benefit of treatment continuation
							with somatropin in patients having acute critical illnesses should be
							weighed against the potential risk.</p>
<p>There have been reports of fatalities after initiating therapy
							with somatropin in pediatric patients with Prader‑Willi
							syndrome who had one or more of the following risk factors: severe
							<span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, history of upper airway obstruction or <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>, or
							unidentified <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infection</span>. Male patients with one or more of
							these factors may be at greater risk than females. Patients with
							Prader‑Willi syndrome should be evaluated for signs of upper
							airway obstruction and <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span> before initiation of treatment with
							somatropin. If, during treatment with somatropin, patients show signs of
							upper airway obstruction (including onset of or increased <span class="product-label-link" type="condition" conceptid="4248728" conceptname="Snoring">snoring</span>)
							and/or new onset <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>, treatment should be interrupted. All
							patients with Prader‑Willi syndrome treated with somatropin
							should also have effective weight control and be monitored for signs of
							<span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infection</span>, which should be diagnosed as early as possible
							and treated aggressively (see <a href="#Contraindications">CONTRAINDICATIONS</a>). Unless patients with
							Prader‑Willi syndrome also have a diagnosis of growth hormone
							deficiency, Nutropin is not indicated for the long‑term
							treatment of pediatric patients who have growth failure due to
							genetically confirmed Prader‑Willi syndrome.</p>
<p>Benzyl alcohol as a preservative in Bacteriostatic Water for
							Injection, USP, has been associated with toxicity in newborns. When
							administering Nutropin to newborns, reconstitute with Sterile Water for
							Injection, USP. USE ONLY ONE DOSE PER NUTROPIN VIAL AND DISCARD THE
							UNUSED PORTION.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="34072-9">
<a name="precautions_general"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Nutropin should be prescribed by physicians experienced
									in the diagnosis and management of patients with GH deficiency,
									idiopathic <span class="product-label-link" type="condition" conceptid="440076" conceptname="Short stature disorder">short stature</span>, Turner syndrome, or chronic renal
									insufficiency. No studies have been completed evaluating
									Nutropin therapy in patients who have received renal
									transplants. Currently, treatment of patients with functioning
									renal allografts is not indicated.</p>
<p>Treatment with somatropin may decrease insulin
									sensitivity, particularly at higher doses in susceptible
									patients. As a result, previously undiagnosed impaired glucose
									tolerance and overt <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus may be unmasked during
									somatropin treatment. Therefore, glucose levels should be
									monitored periodically in all patients treated with somatropin,
									especially in those with risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus,
									such as <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> (including obese patients with Prader-Willi
									syndrome), Turner syndrome, or a family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>
									mellitus. Patients with preexisting type 1 or type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>
									mellitus or impaired glucose tolerance should be monitored
									closely during somatropin therapy. The doses of
									antihyperglycemic drugs (i.e., insulin or oral agents) may
									require adjustment when somatropin therapy is instituted in
									these patients.</p>
<p>In subjects treated in a long‑term study of
									Nutropin for idiopathic <span class="product-label-link" type="condition" conceptid="440076" conceptname="Short stature disorder">short stature</span>, mean fasting and
									postprandial insulin levels increased, while mean fasting and
									postprandial glucose levels remained unchanged. Mean hemoglobin
									A<span class="Sub">1c</span> levels rose slightly from baseline as
									expected during adolescence; sporadic values outside normal
									limits occurred transiently.</p>
<p>Nutropin therapy in adults with GH deficiency of adult
									onset was associated with an increase of median fasting insulin
									level in the Nutropin 0.0125 mg/kg/day group from 9.0
									µU/mL at baseline to 13.0 µU/mL at
									Month 12 with a return to the baseline median level
									after a 3‑week post‑washout period of GH
									therapy. In the placebo group there was no change from 8.0
									µU/mL at baseline to Month 12, and after the
									post‑washout period the median level was 9.0 µU/mL. The
									between‑treatment groups difference on change from
									baseline to Month 12 in median fasting insulin level
									was significant, p&lt;0.0001. In childhood‑onset
									subjects, there was an increase of median fasting insulin level
									in the Nutropin 0.025 mg/kg/day group from 11.0
									µU/mL at baseline to 20.0 µU/mL at
									Month 12, in the Nutropin 0.0125 mg/kg/day
									group from 8.5 µU/mL to 11.0 µU/mL, and in the
									placebo group from 7.0 µU/mL to
									8.0 µU/mL. The
									between‑treatment groups differences for
									these changes were significant, p=0.0007.</p>
<p>In subjects with adult-onset GH deficiency , there were
									no between-treatment group differences on changes from baseline
									to Month 12 in mean HbA<span class="Sub">1c</span> level, p = 0.08. In
									childhood-onset GH deficiency, the mean HbA<span class="Sub">1c</span> level increased in
									the Nutropin 0.025 mg/kg/day group from 5.2% at
									baseline to 5.5% at Month 12, and did not change in the
									Nutropin 0.0125 mg/kg/day group from 5.1% at
									baseline or in the placebo group from 5.3% at baseline.
									The between-treatment group differences were significant, p =
									0.009.</p>
<p>Patients with preexisting tumors or growth hormone
									deficiency secondary to an intracranial lesion should be
									examined routinely for progression or recurrence of the
									underlying disease process. In pediatric patients, clinical
									literature has revealed no relationship between somatropin
									replacement therapy and central nervous system (CNS) tumor
									recurrence or new extracranial tumors. However, in childhood
									cancer survivors, an increased risk of a second neoplasm has
									been reported in patients treated with somatropin after their
									first neoplasm. Intracranial tumors, in particular <span class="product-label-link" type="condition" conceptid="4024298" conceptname="Meningioma">meningiomas</span>,
									in patients treated with radiation to the head for their first
									neoplasm, were the most common of these second neoplasms. In
									adults, it is unknown whether there is any relationship between
									somatropin replacement therapy and CNS tumor recurrence.</p>
<p><span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Intracranial hypertension</span> (IH) with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>, visual
									changes, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> has been reported in
									a small number of patients treated with somatropin products.
									Symptoms usually occurred within the first eight (8) weeks after
									the initiation of somatropin therapy. In all reported cases,
									IH-associated signs and symptoms rapidly resolved after
									cessation of therapy or a reduction of the somatropin dose.
									Funduscopic examination should be performed routinely before
									initiating treatment with somatropin to exclude preexisting
									<span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>, and periodically during the course of somatropin
									therapy. If <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> is observed by funduscopy during
									somatropin treatment, treatment should be stopped. If
									somatropin-induced IH is diagnosed, treatment with somatropin
									can be restarted at a lower dose after IH-associated signs and
									symptoms have resolved. Patients with Turner syndrome, CRI, and
									Prader-Willi syndrome may be at increased risk for the
									development of IH.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="4254542" conceptname="Hypopituitarism">hypopituitarism</span> (multiple hormone
									deficiencies), standard hormonal replacement therapy should be
									monitored closely when somatropin therapy is administered.</p>
<p>Undiagnosed/untreated <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> may prevent an
									optimal response to somatropin, in particular, the growth
									response in children. Patients with Turner syndrome have an
									inherently increased risk of developing autoimmune thyroid
									disease and <span class="product-label-link" type="condition" conceptid="138384" conceptname="Acquired hypothyroidism">primary hypothyroidism</span>. In patients with growth
									hormone deficiency, central (secondary) <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> may first
									become evident or worsen during somatropin treatment. Therefore,
									patients treated with somatropin should have periodic thyroid
									function tests and thyroid hormone replacement therapy should be
									initiated or appropriately adjusted when indicated.</p>
<p>Patients should be monitored carefully for any malignant
									transformation of <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesions</span>.</p>
<p>When somatropin is administered subcutaneously at the
									same site over a long period of time, tissue <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> may result.
									This can be avoided by rotating the injection site.</p>
<p>As with any protein, local or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span>
									may occur. Parents/Patients should be informed that such
									reactions are possible and that prompt medical attention should
									be sought if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First">(see <a href="#precautions_general">PRECAUTIONS,
									General</a>)</p>
<p>Slipped capital femoral epiphysis may occur more
									frequently in patients with <span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">endocrine disorders</span> (including GH
									deficiency and Turner syndrome) or in patients undergoing rapid
									growth. Any pediatric patient with the onset of a limp or
									complaints of hip or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">knee pain</span> during somatropin therapy should
									be carefully evaluated.</p>
<p>Children with growth failure secondary to CRI should be
									examined periodically for evidence of progression of renal
									<span class="product-label-link" type="condition" conceptid="75924" conceptname="Osteodystrophy">osteodystrophy</span>. Slipped capital femoral epiphysis or avascular
									<span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of the femoral head may be seen in children with
									advanced <span class="product-label-link" type="condition" conceptid="197921" conceptname="Renal osteodystrophy">renal osteodystrophy</span>, and it is uncertain whether these
									problems are affected by somatropin therapy. X-rays of the hip
									should be obtained prior to initiating somatropin therapy in CRI
									patients. Physicians and parents should be alert to the
									development of a limp or complaints of hip or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">knee pain</span> in CRI
									patients treated with Nutropin.</p>
<p>Progression of <span class="product-label-link" type="condition" conceptid="72418" conceptname="Scoliosis deformity of spine">scoliosis</span> can occur in patients who
									experience rapid growth. Because somatropin increases growth
									rate, patients with a history of <span class="product-label-link" type="condition" conceptid="72418" conceptname="Scoliosis deformity of spine">scoliosis</span> who are treated with
									somatropin should be monitored for progression of <span class="product-label-link" type="condition" conceptid="72418" conceptname="Scoliosis deformity of spine">scoliosis</span>.
									However, somatropin has not been shown to increase the
									occurrence of <span class="product-label-link" type="condition" conceptid="72418" conceptname="Scoliosis deformity of spine">scoliosis</span>. Skeletal abnormalities including
									<span class="product-label-link" type="condition" conceptid="72418" conceptname="Scoliosis deformity of spine">scoliosis</span> are commonly seen in untreated Turner syndrome
									patients. <span class="product-label-link" type="condition" conceptid="72418" conceptname="Scoliosis deformity of spine">Scoliosis</span> is also commonly seen in untreated patients
									with Prader-Willi syndrome. Physicians should be alert to these
									abnormalities, which may manifest during somatropin therapy.</p>
<p>Patients with Turner syndrome should be evaluated
									carefully for <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> and other <span class="product-label-link" type="condition" conceptid="201577" conceptname="Degenerative and vascular disorders of ear">ear disorders</span> since these
									patients have an increased risk of ear and hearing disorders. In
									a randomized, controlled trial, there was a statistically
									significant increase, as compared to untreated controls, in
									<span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> (43% vs. 26%) and <span class="product-label-link" type="condition" conceptid="201577" conceptname="Degenerative and vascular disorders of ear">ear disorders</span>
									(18% vs. 5%) in patients receiving somatropin.
									In addition, patients with Turner syndrome should be monitored
									closely for <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorders</span> (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, aortic
									<span class="product-label-link" type="condition" conceptid="4311963" conceptname="Aneurysm">aneurysm</span>/dissection, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>) as these patients are also at
									risk for these conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>Adult Patients</h2>
<p class="First">(see <a href="#precautions_general">PRECAUTIONS,
									General</a>)</p>
<p>Patients with epiphyseal closure who were treated with
									somatropin replacement therapy in childhood should be
									reevaluated according to the criteria in <a href="#indications_and_usage">INDICATIONS AND
										USAGE</a> before continuation of somatropin therapy at
									the reduced dose level recommended for GH deficient adults.
									<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> during somatropin replacement therapy in adults
									may occur. Clinical manifestations of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> are
									usually transient and dose dependent (see <a href="#adverse_reactions">ADVERSE REACTIONS</a>).</p>
<p>Experience with prolonged somatropin treatment in adults
									is limited.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients being treated with Nutropin (and/or their
									parents) should be informed about the potential benefits and
									risks associated with Nutropin treatment, including a review of
									the contents of the Patient Information Insert. This information
									is intended to better educate patients (and caregivers); it is
									not a disclosure of all possible adverse or intended effects.</p>
<p>Patients and caregivers who will administer Nutropin
									should receive appropriate training and instruction on the
									proper use of Nutropin from the physician or other suitably
									qualified health care professional. A puncture-resistant
									container for the disposal of used syringes and needles should
									be strongly recommended. Patients and/or parents should be
									thoroughly instructed in the importance of proper disposal, and
									cautioned against any reuse of needles and syringes. This
									information is intended to aid in the safe and effective
									administration of the medication (see Patient Information
									Insert).</p>
<p>See <a href="#Warnings">WARNINGS</a> for
									use of Bacteriostatic Water for Injection, USP, (benzyl alcohol
									preserved), in newborns.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="Laboratory_Tests"></a><a name="section-7.5"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Serum levels of inorganic phosphorus, alkaline
									phosphatase, and parathyroid hormone (PTH) may increase during
									somatropin therapy.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.6"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Somatropin inhibits 11β‑hydroxysteroid
									dehydrogenase type 1 (11βHSD‑1) in
									adipose/hepatic tissue and may significantly impact the
									metabolism of cortisol and cortisone. As a consequence, in
									patients treated with somatropin, previously undiagnosed central
									(secondary) <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span> may be unmasked requiring
									glucocorticoid replacement therapy. In addition, patients
									treated with glucocorticoid replacement therapy for previously
									diagnosed <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span> may require an increase in their
									maintenance or stress doses; this may be especially true for
									patients treated with cortisone acetate and prednisone since
									conversion of these drugs to their biologically active
									metabolites is dependent on the activity of the
									11βHSD‑1 enzyme.</p>
<p>Excessive glucocorticoid therapy may attenuate the
									growth-promoting effects of somatropin in children. Therefore,
									glucocorticoid replacement therapy should be carefully adjusted
									in children with concomitant GH and glucocorticoid deficiency to
									avoid both <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span> and an inhibitory effect on growth.</p>
<p>The use of Nutropin in patients with CRI requiring
									glucocorticoid therapy has not been evaluated. Concomitant
									glucocorticoid therapy may inhibit the growth promoting effect
									of Nutropin. Therefore, if glucocorticoid replacement is
									required for CRI, the glucocorticoid dose should be carefully
									adjusted to avoid an inhibitory effect on growth.</p>
<p>There was no evidence in the controlled studies of
									Nutropin’s interaction with drugs commonly used in chronic renal
									insufficiency patients. Limited published data indicate that
									somatropin treatment increases cytochrome P450 (CP450) mediated
									antipyrine clearance in man. These data suggest that somatropin
									administration may alter the clearance of compounds known to be
									metabolized by CP450 liver enzymes (e.g., corticosteroids, sex
									steroids, anticonvulsants, cyclosporin). Careful monitoring is
									advisable when somatropin is administered in combination with
									other drugs known to be metabolized by CP450 liver enzymes.
									However, formal drug interaction studies have not been
									conducted. </p>
<p>In adult women on oral estrogen replacement, a larger
									dose of somatropin may be required to achieve the defined
									treatment goal (see <a href="#dosage_and_administration">DOSAGE AND ADMINISTRATION</a>).</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus requiring drug
									therapy, the dose of insulin and/or oral agent may require
									adjustment when somatropin therapy is initiated (see <a href="#precautions_general">PRECAUTIONS,
										General</a>).</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.7"></a><p></p>
<h2>Carcinogenesis, Mutagenesis,
								Impairment of Fertility</h2>
<p class="First">Carcinogenicity, mutagenicity, and reproduction studies
									have not been conducted with Nutropin.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.8"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Pregnancy (Category C). Animal reproduction studies have not been
									conducted with Nutropin. It is also not known whether
									Nutropin can cause fetal harm when administered to a
									pregnant woman or can affect reproduction capacity.
									Nutropin should be given to a pregnant woman only if
									clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.9"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether Nutropin is excreted in human
									milk. Because many drugs are excreted in human milk, caution
									should be exercised when Nutropin is administered to a nursing
									mother.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.10"></a><p></p>
<h2>Geriatric Usage</h2>
<p class="First">Clinical studies of Nutropin did not include sufficient
									numbers of subjects aged 65 and over to determine whether they
									respond differently from younger subjects. Elderly patients may
									be more sensitive to the action of somatropin, and therefore may
									be more prone to develop adverse reactions. A lower starting
									dose and smaller dose increments should be considered for older
									patients (see <a href="#dosage_and_administration">DOSING
										AND ADMINISTRATION</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adverse_reactions"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">As with all protein pharmaceuticals, a small percentage of
							patients may develop antibodies to the protein. GH antibody binding
							capacities below 2 mg/L have not been associated with growth
							attenuation. In some cases when binding capacity exceeds
							2 mg/L, growth attenuation has been observed. In clinical
							studies of pediatric patients that were treated with Nutropin for the
							first time, 0/107 growth hormone–deficient (GHD)
							patients, 0/125 CRI patients, 0/112 Turner
							syndrome, and 0/117 ISS patients screened for antibody
							production developed antibodies with binding capacities ≥
							2 mg/L at six months.</p>
<p>Additional short‑term immunologic and renal function
							studies were carried out in a group of patients with CRI after
							approximately one year of treatment to detect other potential
							adverse effects of antibodies to GH. Testing included measurements of
							C1q, C3, C4, rheumatoid factor, creatinine, creatinine clearance, and
							BUN. No adverse effects of GH antibodies were noted.</p>
<p>In addition to an evaluation of compliance with the prescribed
							treatment program and thyroid status, testing for antibodies to GH
							should be carried out in any patient who fails to respond to therapy.</p>
<p>In a post‑marketing surveillance study, the National
							Cooperative Growth Study, the pattern of adverse events in over
							8000 patients with idiopathic <span class="product-label-link" type="condition" conceptid="440076" conceptname="Short stature disorder">short stature</span> was consistent with
							the known safety profile of GH, and no new safety signals attributable
							to GH were identified. The frequency of protocol‑defined
							targeted adverse events is described in the table, below.</p>
<table width="50%">
<caption><span>Protocol‑Defined Targeted Adverse Events in the ISS
								NCGS Cohort</span></caption>
<col align="left">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<thead><tr class="First Last">
<th class="Lrule" align="center" valign="bottom">Reported
										Events</th>
<th class="Rrule" align="center" valign="bottom">NCGS<br>(N=8018)</th>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="5">AVN=<span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">avascular necrosis</span>;
										SCFE=slipped capital femoral epiphysis.</td></tr>
<tr class="Last"><td align="left" colspan="5">Data obtained with several rhGH
										products (Nutropin, Nutropin AQ, Nutropin Depot and
										Protropin).</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Any adverse event</td>
<td class="Rrule" align="center"> </td>
</tr>
<tr>
<td class="Lrule" align="left"> Overall</td>
<td class="Rrule" align="center">103 (1.3%)</td>
</tr>
<tr>
<td class="Lrule" align="left">Targeted adverse event</td>
<td class="Rrule" align="center"> </td>
</tr>
<tr>
<td class="Lrule" align="left"> Overall</td>
<td class="Rrule" align="center">103 (1.3%)</td>
</tr>
<tr>
<td class="Lrule" align="left"> Injection-site reaction</td>
<td class="Rrule" align="center">28 (0.3%)</td>
</tr>
<tr>
<td class="Lrule" align="left"> New onset or progression of
										<span class="product-label-link" type="condition" conceptid="72418" conceptname="Scoliosis deformity of spine">scoliosis</span></td>
<td class="Rrule" align="center">16 (0.2%)</td>
</tr>
<tr>
<td class="Lrule" align="left"> <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span></td>
<td class="Rrule" align="center">12 (0.1%)</td>
</tr>
<tr>
<td class="Lrule" align="left"> Any new onset or recurring tumor
										(benign)</td>
<td class="Rrule" align="center">12 (0.1%)</td>
</tr>
<tr>
<td class="Lrule" align="left"> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> or <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span></td>
<td class="Rrule" align="center">10 (0.1%)</td>
</tr>
<tr>
<td class="Lrule" align="left"> <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> mellitus</td>
<td class="Rrule" align="center">5 (0.1%)</td>
</tr>
<tr>
<td class="Lrule" align="left"> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Rrule" align="center">5 (0.1%)</td>
</tr>
<tr>
<td class="Lrule" align="left"> Cancer, neoplasm (new onset or
										recurrence)</td>
<td class="Rrule" align="center">4(0.0%)</td>
</tr>
<tr>
<td class="Lrule" align="left"> <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></td>
<td class="Rrule" align="center">4(0.0%)</td>
</tr>
<tr>
<td class="Lrule" align="left"> <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Intracranial hypertension</span></td>
<td class="Rrule" align="center">4(0.0%)</td>
</tr>
<tr>
<td class="Lrule" align="left"> Abnormal bone or other growth</td>
<td class="Rrule" align="center">3(0.0%)</td>
</tr>
<tr>
<td class="Lrule" align="left"> Central nervous system tumor</td>
<td class="Rrule" align="center">2(0.0%)</td>
</tr>
<tr>
<td class="Lrule" align="left"> New or recurrent SCFE or AVN</td>
<td class="Rrule" align="center">2(0.0%)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"> <span class="product-label-link" type="condition" conceptid="380094" conceptname="Carpal tunnel syndrome">Carpal tunnel syndrome</span></td>
<td class="Rrule" align="center">1(0.0%)</td>
</tr>
</tbody>
</table>
<p>In studies in patients treated with Nutropin, <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>
							was reported infrequently.</p>
<p><span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span> has been reported in a small number of GHD patients
							treated with GH. It is uncertain whether this increased risk is related
							to the pathology of GH deficiency itself, GH therapy, or other
							associated treatments such as radiation therapy for intracranial tumors.
							On the basis of current evidence, experts cannot conclude that GH
							therapy is responsible for these occurrences. The risk to GHD, CRI, or
							Turner syndrome patients, if any, remains to be established.</p>
<p>Other adverse drug reactions that have been reported in
							GH‑treated patients include the following:</p>
<dl>
<dt>1)</dt>
<dd>Metabolic: mild, transient <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>.
								In GHD adults, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> was reported in 41%
								of GH‑treated patients and 25% of
								placebo‑treated patients;</dd>
<dt>2)</dt>
<dd>Musculoskeletal: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>; carpal tunnel
								syndrome. In GHD adults, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span> and other <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">joint disorders</span> were
								reported in 27% of GH‑treated patients and
								15% of placebo‑treated patients;</dd>
<dt>3)</dt>
<dd>Skin: rare increased growth of
								pre‑existing nevi; patients should be monitored for
								malignant transformation; and</dd>
<dt>4)</dt>
<dd>Endocrine: <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>. Rare
								<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Acute overdosage could lead to <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. Long‑term
							overdosage could result in signs and symptoms of gigantism and/or
							<span class="product-label-link" type="condition" conceptid="4253197" conceptname="Acromegaly">acromegaly</span> consistent with the known effects of excess GH. (See
							recommended and maximal dosage instructions given below.)</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosage_and_administration"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The Nutropin<span class="Sup">®</span> [somatropin (rDNA origin) for
							injection] dosage and administration schedule should be individualized
							for each patient. Response to growth hormone therapy in pediatric
							patients tends to decrease with time. However, in pediatric patients
							failure to increase growth rate, particularly during the
							first year of therapy, suggests the need for close assessment
							of compliance and evaluation of other causes of growth failure, such as
							<span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, under‑nutrition, and advanced bone
							age.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Dosage</h2>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1.1"></a><p></p>
<h3>Pediatric Growth Hormone
										Deficiency (GHD)</h3>
<p class="First">A weekly dosage of up to 0.3 mg/kg of
											body weight divided into daily subcutaneous injection is
											recommended. In pubertal patients, a weekly dosage of up
											to 0.7 mg/kg divided daily may be
											used.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1.2"></a><p></p>
<h3>Adult Growth Hormone
										Deficiency (GHD)</h3>
<p class="First">Based on the weight-based dosing utilized in the
											original pivotal studies described herein, the
											recommended dosage at the start of therapy is not more
											than 0.006 mg/kg given as a daily subcutaneous
											injection. The dose may be increased according to
											individual patient requirements to a maximum of 0.025
											mg/kg daily in patients under 35 years old and to a
											maximum of 0.0125 mg/kg daily in patients over
											35 years old. Clinical response, side effects, and
											determination of age- and gender-adjusted serum IGF-I
											levels may be used as guidance in dose titration.</p>
<p>Alternatively, taking into account more recent
											literature, a starting dose of approximately
											0.2 mg/day (range,
											0.15‑0.30 mg/day) may be used without
											consideration of body weight. This dose can be increased
											gradually every 1-2 months by increments of
											approximately 0.1-0.2 mg/day, according to individual
											patient requirements based on the clinical response and
											serum IGF-I concentrations. During therapy, the dose
											should be decreased if required by the occurrence of
											adverse events and/or serum IGF-I levels above the age-
											and gender-specific normal range. Maintenance dosages
											vary considerably from person to person.</p>
<p>A lower starting dose and smaller dose increments
											should be considered for older patients, who are more
											prone to the adverse effects of somatropin than younger
											individuals. In addition, obese individuals are more
											likely to manifest adverse effects when treated with a
											weight-based regimen. In order to reach the defined
											treatment goal, estrogen-replete women may need higher
											doses than men. Oral estrogen administration may
											increase the dose requirements in women.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1.3"></a><p></p>
<h3>Chronic Renal
										Insufficiency (CRI)</h3>
<p class="First">A weekly dosage of up to 0.35 mg/kg of
											body weight divided into daily subcutaneous injection is
											recommended.</p>
<p>Nutropin therapy may be continued up to the time
											of renal transplantation.</p>
<p>In order to optimize therapy for patients who
											require dialysis, the following guidelines for injection
											schedule are recommended:</p>
<ol>
<li>Hemodialysis patients should receive their
												injection at night just prior to going to sleep or
												at least 3–4 hours after their
												hemodialysis to prevent <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> formation due to
												the heparin.</li>
<li>Chronic Cycling Peritoneal Dialysis (CCPD)
												patients should receive their injection in the
												morning after they have completed dialysis.</li>
<li>Chronic Ambulatory Peritoneal Dialysis (CAPD)
												patients should receive their injection in the
												evening at the time of the overnight
												exchange.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1.4"></a><p></p>
<h3>Turner Syndrome</h3>
<p class="First">A weekly dosage of up to 0.375 mg/kg of
											body weight divided into equal doses 3 to
											7 times per week by subcutaneous injection is
											recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1.5"></a><p></p>
<h3>Idiopathic <span class="product-label-link" type="condition" conceptid="440076" conceptname="Short stature disorder">Short Stature</span>
										(ISS)</h3>
<p class="First">A weekly dosage of up to 0.3 mg/kg of
											body weight divided into daily subcutaneous injection
											has been shown to be safe and efficacious, and is
											recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Administration</h2>
<p class="First">After the dose has been determined, reconstitute as
									follows: each 5 mg vial should be reconstituted with
									1–5 mL of Bacteriostatic Water for Injection,
									USP (benzyl alcohol preserved); or each 10 mg vial
									should be reconstituted with 1–10 mL of
									Bacteriostatic Water for Injection, USP (benzyl alcohol
									preserved), only. For use in newborns, see <a href="#Warnings">WARNINGS</a>. The pH of Nutropin
									after reconstitution with Bacteriostatic Water for Injection,
									USP (benzyl alcohol preserved), is approximately 7.4.</p>
<p>To prepare the Nutropin solution, inject the
									Bacteriostatic Water for Injection, USP (benzyl alcohol
									preserved) into the Nutropin vial, aiming the stream of liquid
									against the glass wall. Then swirl the product vial with a
									<span class="Bold">GENTLE</span> rotary motion
									until the contents are completely dissolved. <span class="Bold"> DO NOT SHAKE </span>. Because Nutropin
									is a protein, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> can result in a cloudy solution. The
									Nutropin solution should be clear immediately after
									reconstitution. Occasionally, after refrigeration, you may
									notice that small colorless particles of protein are present in
									the Nutropin solution. This is not unusual for solutions
									containing proteins. If the solution is cloudy immediately after
									reconstitution or refrigeration, the contents <span class="Bold">MUST NOT </span>be injected.</p>
<p>Before needle insertion, wipe the septum of both the
									Nutropin and diluent vials with rubbing alcohol or an antiseptic
									solution to prevent contamination of the contents by
									microorganisms that may be introduced by repeated needle
									insertions. It is recommended that Nutropin be administered
									using sterile, disposable syringes and needles. The syringes
									should be of small enough volume that the prescribed dose can be
									drawn from the vial with reasonable accuracy.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1>STABILITY AND STORAGE</h1>
<p class="First">Before Reconstitution—Nutropin and Bacteriostatic Water
							for Injection, USP (benzyl alcohol preserved), must be stored at
							2–8°C/36–46°F (under
							refrigeration). <span class="Bold"> Avoid freezing the vials of
								Nutropin and Bacteriostatic Water for Injection, USP (benzyl alcohol
								preserved).</span> Expiration dates are stated on the labels.</p>
<p>After Reconstitution—Vial contents are stable for
							14 days when reconstituted with Bacteriostatic Water for
							Injection, USP (benzyl alcohol preserved), and stored at
							2–8°C/36–46°F (under
							refrigeration). <span class="Bold"> Avoid freezing the
								reconstituted vial of Nutropin and the Bacteriostatic Water for
								Injection, USP (benzyl alcohol preserved). </span></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="how-supplied"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Nutropin<span class="Sup">®</span> [somatropin (rDNA origin) for
							injection] is supplied as 5 mg (approximately 15 IU)
							or 10 mg (approximately 30 IU) of lyophilized, sterile
							somatropin per vial.</p>
<p>Each 5 mg carton contains one vial of Nutropin®
							[somatropin (rDNA origin) for injection] (5 mg per vial) and
							one 10 mL multiple dose vial of Bacteriostatic Water for
							Injection, USP (benzyl alcohol preserved).
							NDC 50242‑072‑03.</p>
<p>Each 10 mg carton contains one vial of Nutropin®
							[somatropin (rDNA origin) for injection] (10 mg per vial) and
							one 10 mL multiple dose vial of Bacteriostatic Water for
							Injection, USP (benzyl alcohol preserved).
							NDC 50242‑018‑21.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1></h1>
<table width="600">
<col width="50%">
<col width="50%">
<tbody class="Headless"><tr class="First Last">
<td align="left" valign="top">
<p class="First">Nutropin<span class="Sup">®</span><br>[somatropin (rDNA origin) for injection]<br>Manufactured by:<br><span class="Bold">Genentech, Inc.</span><br>1 DNA Way<br>South San Francisco, CA  94080–4990<br><br></p>
<p>Bacteriostatic Water for Injection, USP <br>(benzyl alcohol preserved),<br>Manufactured for:<br>Genentech, Inc.</p>
</td>
<td align="right" valign="top"><p class="First">7123911<br>LF0563<br>(4834502)<br>FDA Approval Date June 2006<br>Code Revision Date June 2006<br><span class="Sup">©</span>2005 Genentech, Inc.</p></td>
</tr></tbody>
</table>
<p class="First">
							Representative sample of labeling (see the <a href="#how-supplied">HOW SUPPLIED</a> section for complete listing):
						</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1></h1>
<div class="Figure">
<img alt="Principal Display Panel - 5 mg Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e6574a25-1ad5-4946-b750-501ce745574f&amp;name=nutropin-pdp-01.jpg"><p class="MultiMediaCaption">Principal Display Panel - 5 mg Vial Carton</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1></h1>
<div class="Figure">
<img alt="Principal Display Panel - 10 mg Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e6574a25-1ad5-4946-b750-501ce745574f&amp;name=nutropin-pdp-02.jpg"><p class="MultiMediaCaption">Principal Display Panel - 10 mg Vial Carton</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NUTROPIN 		
					</strong><br><span class="contentTableReg">somatropin kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50242-072</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50242-072-03</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, MULTI-DOSE </td>
<td class="formItem">10 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>SOMATROPIN 		
					</strong><br><span class="contentTableReg">somatropin injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SOMATROPIN</strong> (SOMATROPIN) </td>
<td class="formItem">SOMATROPIN</td>
<td class="formItem">5 mg  in 5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">45 mg  in 5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, MONOBASIC</strong></td>
<td class="formItem">0.4 mg  in 5 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem">1.3 mg  in 5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCINE</strong></td>
<td class="formItem">1.7 mg  in 5 mg</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mg in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019676</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>BACTERIOSTATIC WATER 		
					</strong><br><span class="contentTableReg">water solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019676</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019676</td>
<td class="formItem">11/17/1993</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NUTROPIN 		
					</strong><br><span class="contentTableReg">somatropin kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50242-018</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50242-018-21</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, MULTI-DOSE </td>
<td class="formItem">10 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>SOMATROPIN 		
					</strong><br><span class="contentTableReg">somatropin injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SOMATROPIN</strong> (SOMATROPIN) </td>
<td class="formItem">SOMATROPIN</td>
<td class="formItem">10 mg  in 10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">90 mg  in 10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, MONOBASIC</strong></td>
<td class="formItem">0.8 mg  in 10 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem">2.6 mg  in 10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCINE</strong></td>
<td class="formItem">3.4 mg  in 10 mg</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mg in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019676</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>BACTERIOSTATIC WATER 		
					</strong><br><span class="contentTableReg">water solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019676</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019676</td>
<td class="formItem">11/17/1993</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Genentech, Inc.
							(080129000)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Genentech, Inc. (080129000)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genentech, Inc. (SSF)</td>
<td class="formItem"></td>
<td class="formItem">080129000</td>
<td class="formItem">API MANUFACTURE, MANUFACTURE, ANALYSIS</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>38f61741-b766-426c-a441-ba09198973da</div>
<div>Set id: e6574a25-1ad5-4946-b750-501ce745574f</div>
<div>Version: 3</div>
<div>Effective Time: 20120306</div>
</div>
</div> <div class="DistributorName">Genentech, Inc.</div></p>
</body></html>
